CCL24 recruits CCR3&lt;sup&gt;+&lt;/sup&gt; TAMs to promote immunosuppression via YAP1 activation and serves as a therapeutic target for Gracillin in colorectal cancer. This evidence concerns the gene CCL24 and colorectal cancer.